Chief Commercial Officer (CCO), Member of the Corporate Executive Board
Janneke van der Kamp, Chief Commercial Officer
“I strive to build and nurture an inclusive and collaborative work environment so that we can deliver the best treatments for patients.”
Orchestrating success and hitting the high notes – Janneke van der Kamp is instrumental in more ways than one, whether developing global commercial strategies or expertly playing the violin.
Originally from The Netherlands, she joins Grünenthal from Novartis, where she gained two decades of experience, most recently as Head of Pharma Region Europe and Global Head of Product & Portfolio Strategy.
Her outstanding track record in leading diverse, driven teams and launching industry-leading brands is a huge asset to Grünenthal’s growing portfolio, and help ensure that together, we can successfully bring new medicines to patients.
Janneke van der Kamp at a glance
Nationality: Dutch
Year of birth: 1975
Education: Utrecht University: Master of Science in Chemistry (with distinction) and won prestigious national award for Masters research in protein NMR; Rotterdam’s Conservatorium: Bachelor of Music – Violin; INSEAD: Master of Business Administration (with distinction)
Family status: Married, 2 children
Leisure time: Violin, skiing, hiking
Career highlights
1999-2002: Strategy Consultant, ArthurDLittle and Roland Berger Strategy consultants
2003-2007: Brand Management, Sales and Sales Management roles in UK, NL, CH, Novartis
2008: Head of Business Operations and Strategic Projects Europe, Novartis
2009-2011: Marketing Director, Novartis NL
2012-2014: General Manager Novartis Pharma Belgium & Luxembourg
2014-2016: Global Business Franchise Head, Neuroscience, Novartis
2016-2018: Global Head Product & Portfolio Strategy, Novartis
2019-2022: Head Region Europe Pharma, Novartis
Since 2023: Member of the Board of Directors at NewAmsterdam Pharma Company, a clinical-stage biopharmaceutical company focused on the research and development of transformative oral therapies for major cardiometabolic diseases.